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Viruses that cause chronic infection constitute a stable but little-recognized part of our meta-
genome: our virome. Ongoing immune responses hold these chronic viruses at bay while 
avoiding immunopathologic damage to persistently infected tissues. The immunologic imprint 
generated by these responses to our virome defines the normal immune system. The resulting 
dynamic but metastable equilibrium between the virome and the host can be dangerous, 
benign, or even symbiotic. These concepts require that we reformulate how we assign etiolo-
gies for diseases, especially those with a chronic inflammatory component, as well as how 
we design and interpret genome-wide association studies, and how we vaccinate to limit or 
control our virome.Our metagenome includes all organisms that live on us or in us. 
The bacteria that colonize us can vary from being symbionts to 
opportunists to pathogens, with the balance between extreme 
outcomes of infection determined by host immunity and bacte-
rial virulence. Commensal bacteria are known to regulate the 
host immune response and systemic physiology in fundamen-
tally important ways. Less recognized are the contributions to 
our metagenome from viruses that establish chronic infection 
and retroviral elements that infest our chromosomes. How the 
dynamic nature of the interactions between this internal virome 
and the host imprints our immune system, and perhaps our 
physiology more generally, has been given little consideration. 
Some chronic infections are so common that any immuno-
logic imprint of these agents or potential contribution of these 
viruses to disease are obscured by the fact that they are part 
of the normal flora of most humans. Thus, a redefinition of 
chronic virus infection that sets the stage for new and interest-
ing experiments is needed to analyze this fundamental aspect 
of our biology. We all carry, for good or ill, many lifelong viral 
passengers.
Comparing Acute and Chronic Viral Infection
Acute viral infection is a nonequilibrium process, whereas 
chronic viral infection is a process in dynamic and metastable 
equilibrium. During acute infection, both the host and virus 
change continuously until infection is resolved, kills the host, or 
becomes chronic (Figure 1). Certain genes in a virus or in the 
immune system are niche specific in that they function during 
acute but not chronic infection. Failure of these immune sys-
tem genes to function effectively or too-effective evasion of 
immunity by viral genes can have devastating consequences. In 
contrast, during chronic infection, viral and host genes balance 
each other. How some viruses manage to persist despite the 
impressive immune armamentarium of the host, without causing 
overt disease, is a great unsolved mystery in immunobiology.30 Cell 138, July 10, 2009 ©2009 Elsevier Inc.Our understanding of host immunity and viral virulence 
comes largely from studies of resolving acute infection (Fig-
ure 1). Clearance of viral antigen, effector cells, and cytok-
ines allows the immune system to reset to an uninfected but 
memory-armed state that includes quiescent “hair-triggered” 
memory B and T cells, as well as plasma cells that continu-
ously produce antibody. Studies of acute infection have been 
extremely valuable for defining viral virulence and host immu-
nity. However, the “viral” and “host” rules that govern acute 
versus chronic viral infection differ markedly. For example, 
whereas CD8 T cells that recognize peptides presented by 
classical major histocompatibility complex (MHC) molecules 
are important during both acute and chronic infection, CD8 T 
cell responses restricted by nonclassical MHC molecules play 
an important part in the control of some chronic viral infec-
tions (Braaten et al., 2006; Swanson et al., 2008; Moretta et 
al., 2003).
Two events are fundamental to establishment of chronic 
viral infection (Figure 1). First, the virus must evade sterilizing 
immunity (the complete elimination of a virus). Second, the 
immune system must adjust to the continuous presence of viral 
antigen-driven inflammatory responses in order to limit viral 
replication to an acceptable level without untoward damage 
to permanently infected tissues. If the immune system can-
not eliminate the virus, unrestrained immune attack on virus 
antigen-bearing cells causes immunopathology. Thus, down-
regulation of inflammation during chronic viral infections can 
result in decreased tissue damage, at least for noncytopathic 
viruses. Immunopathology can be severe in animal models and 
has been implicated in human chronic infections caused by 
hepatitis B virus (HBV) and hepatitis C virus (HCV) (Guidotti 
and Chisari, 2006). It is important to realize that viruses that 
rely on a living but chronically infected host for their own sur-
vival must carefully avoid mechanisms that overwhelm immu-
nity and kill their hosts. Indeed, given the rapid pace of viral 
evolution, it stands to reason that viruses that are relatively 
benign clinically, despite establishing chronic infection, would 
have evolved to greater virulence if this was advantageous.
The balances between the vigor of the antiviral immune 
response, immunopathology, and viral strategies for main-
taining chronic infection without killing the host are poorly 
understood. Importantly, even when the host and virus are in a 
metastable equilibrium, chronic infection is dynamic, with host 
and viral processes balanced on a knife’s edge such that small 
changes can disrupt the equilibrium with unfortunate conse-
quences. This dynamism has fundamentally important effects 
on the host, including setting a level of cytokines in tissues and 
serum that may alter the function of innate immunity, antigen-
presenting cells (APC), and lymphocytes. An example of the 
timeframe involved in establishing such relationships comes 
from herpesviruses, which derive from an ancestral virus shared 
by birds, reptiles, and mammals (McGeoch et al., 2006) and 
have therefore shared more than 100 million years of coevolu-
tion with their current hosts. Given the length of this genetic 
relationship, it is highly likely that adaptations in both host and 
viral genomes enhance our capacity to coexist with these age-
old passengers. These complex interactions between virus 
and host form an intricate network of interdependent genes 
and processes that must be understood in molecular detail if 
we seek to intervene without causing harm.
Persistent Viruses: Old Enemies and New Passengers
It would be most appropriate to categorize viruses that estab-
lish chronic infection by the mechanisms used to establish per-
sistence, but these are ill defined. We categorized them here by 
the estimated prevalence of chronic human infection to empha-
size the contribution of our virome to our metagenome (Table 
1, Figure 2). The numbers in Figure 2 are extrapolations to the 
entire earth’s population from the esti-
mated prevalence of antiviral antibod-
ies in serum (seroprevalence) (Table 1). 
Because seroprevalence data are often 
obtained only from developed coun-
tries, the impact of chronic infections on 
humanity as a whole is poorly character-
ized. This is an important deficiency in 
our current understanding of the human 
metagenome. However, a rough calculation reveals that there 
are many billions of chronic virus infections in humans, with 
each of the ~6.75 billion of us harboring ~8–12 chronic infec-
tions (Figure 2, Table 1). Some of these viruses are so common 
that one would be hard put to find uninfected control patients 
for studies to identify viral associations with disease or effects 
on the “normal” immune system. The fact that most of us do 
not show obvious symptoms of these infections marks these 
viruses as part of the metagenome of normal individuals. This 
formulation is not meant to detract from the obvious point that 
some of these viruses cause human disease. Rather, it calls 
attention to the need to seriously consider what these infec-
tions mean for humans without overt disease and the need to 
understand chronic diseases that are considered “nonviral” 
based on our inability to compare infected to noninfected indi-
viduals.
Little is known about some of the viruses that inhabit us. 
This is due to the focus of research on viruses that cause 
disease in a high proportion of infected individuals. Many of 
the most prevalent chronic virus infections only rarely cause 
disease, are not associated with any disease at all, or cause 
disease primarily in immunocompromised individuals (Figure 
2, Table 1). In contrast, some of the best understood viruses 
such as HCV, HBV, and human immunodeficiency virus (HIV) 
are of great medical importance but infect a lower proportion 
of the human population in comparison to their less virulent 
counterparts (Figure 2, Table 1). Other viruses rarely establish 
chronic infection but when they do, they are highly virulent. For 
example, measles virus can cause relentlessly progressing 
neurogenerative disease (Table 1).
Importantly, the number of recognized persistent viruses has 
increased with the advent of new molecular technologies. For 
example, there are five human polyomaviruses, three of which 
Figure 1. The Course of Viral Infection
When a virus enters the host, there is an initial 
nonequilibrium phase of acute infection. During 
this phase, viral and immune strategies compete 
for dominance. Assuming the host survives, a 
decision point is reached at which the infection 
is either cleared or becomes chronic. This deci-
sion point may be reached very early in infection 
for viruses that can establish a latent infection, in 
which case the infection is permanent regardless 
of the course of acute infection. If recovery occurs, 
the immune system must reset by clearing the an-
tigen and re-establishing immune homeostasis. If 
the balance shifts toward chronic infection, a new 
set of viral and host strategies interact to define a 
metastable equilibrium in which viral replication is 
held in check, but the virus is not cleared.Cell 138, July 10, 2009 ©2009 Elsevier Inc. 31
Table 1. Chronic Virus Infections in Humans
Disease during Chronic Infection
Virus, Primary Nucleic 
Acid, Estimated Percent 
of Humans Infected
Major Site of 
 Persistence  
(Organ or Cell)
Acute Infection 
Examples
Within Normal Hosts Within Immunocompromised 
Hosts
References
Endogenous retrovirus-
es (ERV), DNA, 100%
All Not applicable Unknown Unknown Seifarth et al., 2005; Virgin, 
2007b
Anellovirus/Circovirus, 
DNA, 90%–100%
Many tissues Unknown Unknown Unknown Davidson and Shulman, 
2008; Ninomiya et al., 
2008; Hino and Miyata, 
2007
Human herpesvirus 6 
(HHV-6), DNA, >90%
Lymphocytes? Roseola Unknown Meningoencephalitis, sec-
ondary infections, immuno-
modulatory? 
Straus, 2000; Yamanishi et 
al., 2007
Human herpesvirus 7 
(HHV-7), DNA, >90%
Lymphocytes? Roseola Unknown Unknown Straus, 2000; Yamanishi et 
al., 2007
Varicella zoster virus 
(VZV), DNA, >90%
Sensory ganglia 
neurons and/
or satellite cells, 
lymphocytes
Chicken pox Herpes zoster Disseminated disease, hepa-
titis, pneumonitis
Zerboni and Arvin, 2008; 
Straus, 2000
Cytomegalovirus (CMV), 
DNA, 80%–90%
Myelomonocytic 
cells
Mononucleosis Rare Disseminated disease, vas-
culitis, pneumonitis, retinitis, 
hepatitis, gastroenteritis, 
meningoencephalitis
Mocarski et al., 2007
Epstein-Barr virus 
(EBV), DNA, 80%–90%
Pharyngeal 
epithelial cells, 
B cells
Mononucleosis Burkitt’s lymphoma, 
nasopharyngeal carci-
noma, non-Hodgkin’s 
lymphoma
CNS lymphomas, oral hairy 
leukoplakia, lymphoproliferative 
disease
Rickinson and Kieff, 2007; 
Straus, 2000; Kieff and 
Rickinson, 2007
Polyomavirus BK, DNA, 
72%–98%
Kidney Unknown Unknown Hemorrhagic cystitis (post 
bone marrow transplantation), 
nephropathy (post kidney 
transplantation)
Zur, 2008
Polyomavirus JC, DNA, 
72%–98%
Kidney, CNS Unknown Unknown Progressive multifocal leuko-
encephalopathy 
Zur, 2008
Adeno-associated virus 
(AAV), DNA, 60%–90%
Many tissues Unknown Unknown Unknown Gao et al., 2004; Berns 
and Parrish, 2008; Sch-
nepp et al., 2005a, 2005b; 
Chen et al., 2005; Erles et 
al., 1999; Blacklow et al., 
1968
Herpes simplex type 
1 (HSV-1), DNA, 
50%–70% 
Sensory ganglia 
neurons
Pharyngitis, 
encephalitis, 
keratitis, 
Cold sores, encephali-
tis, keratitis
Increased severity of same dis-
eases, pneumonitis, hepatitis
Straus, 2000
Adenovirus, DNA, up 
to 80%
Adenoids, ton-
sils, lymphocytes
Upper respira-
tory infection, 
gastroenteritis
Unknown Enteritis, hemorrhagic cystitis, 
pneumonitis, hepatitis, others
Garnett et al., 2002; Wold 
and Horwitz, 2008
Herpes simplex type 
2 (HSV-2), DNA, 
20%–50%
Sensory ganglia 
neurons
Genital herpes Genital herpes, en-
cephalitis
Increased severity of same 
diseases
Straus, 2000
Kaposi’s sarcoma 
herpesvirus (KSHV) or 
human herpesvirus 8, 
DNA, 2%–60%
Endothelial cells, 
B cells
Unknown Castleman’s disease, 
Kaposi’s sarcoma
Kaposi’s sarcoma, primary ef-
fusion lymphoma
Ganem, 2006
Hepatitis B virus (HBV), 
DNA, 350 million, ~5%
Hepatocytes Hepatitis Cirrhosis, hepatocel-
lular carcinoma
Same diseases McGovern, 2007; Re-
hermann and Nascimbeni, 
2005
GB virus C, RNA, 
1%–4%
Lymphocytes Unknown Unknown Unknown Stapleton et al., 2004; 
Berzsenyi et al., 2005
Papilloma virus, DNA, 
<5%
Epithelial skin 
cells
Unknown Papilloma, cervical 
and other mucosal 
carcinomas
Increased severity and inci-
dence of same diseases
Leggatt and Frazer, 2007; 
Howley and Lowy, 2007
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Table 1. Continued
Disease during Chronic Infection
Virus, Primary Nucleic 
Acid, Estimated Percent 
of Humans Infected
Major Site of Per-
sistence (Organ 
or Cell)
Acute Infection 
Examples
Within Normal Hosts Within Immunocompromised 
Hosts
References
Hepatitis C virus (HCV), 
RNA, 170 million,~2.5%
Hepatocytes Hepatitis Cirrhosis, hepatocel-
lular carcinoma
Same diseases Rehermann and 
 Nascimbeni, 2005; Lemon 
et al., 2007
Human immunodefi-
ciency virus (HIV-1 and 
HIV-2), RNA, 33 million, 
~0.5%
CD4+ T 
cells, monocyte/
macrophages 
Acute febrile 
illness
AIDS AIDS UNAIDS, 2008; Kuritzkes 
and Walter, 2007
Hepatitis D virus (HDV), 
RNA, 15 million, ~0.2%
Hepatocytes Unknown Exacerbation of 
chronic HBV infection
Unknown Taylor et al., 2007
Human T cell leukemia 
virus type 1 (HTLV1), 
RNA, 10–20 million, 
~0.2%
T cells Unknown Adult T cell leukemia 
(2%–6% of carriers), 
tropical spastic para-
paresis, myelopathy, 
uveitis, dermatitis
Unknown Matsuoka and Jeang, 
2007; Lairmore and 
 Franchini, 2007
Xenotropic murine leu-
kemia virus-related virus 
(XMLV), RNA, unknown
Prostate Unknown Prostate Cancer? Unknown Urisman et al., 2006; Dong 
et al., 2007
HTLV II, III, IV, RNA, 
unknown
T cells Unknown Unknown Unknown Matsuoka and Jeang, 
2007; Lairmore and 
 Franchini, 2007
Polyomavirus MC, DNA, 
unknown
Merkel cell 
carcinoma
Unknown Merkel cell carci-
noma?
Unknown Zur, 2008
Polyomavirus KI, DNA, 
unknown
Lung Unknown Unknown Unknown Zur, 2008
Polyomavirus WU, DNA, 
unknown
Lung Unknown Unknown Unknown Zur, 2008
Rubella virus, German 
measles, RNA, rare
CNS Rubella, arthritis Progressive rubella 
panencephalitis
Unknown Hobman and Chantler, 
2007
Parvovirus B19, DNA, 
rare
Bone marrow 
erythroid pro-
genitors
Fifth disease, 
arthritis
Aplastic crisis in 
hemolytic anemia, 
hydrops fetalis, 
chronic bone marrow 
deficiency
Red cell aplasia Berns and Parrish, 2008; 
Norja et al., 2008
Measles virus, RNA, 
rare
Neurons and 
supporting cells 
in CNS
Measles Subacute scleros-
ing panencephalitis, 
measles inclusion 
body encephalitis
Unknown Griffin, 2007
Coxsackie, RNA, rare Myocardial cells Hand foot and 
mouth disease, 
herpangina
Myocarditis Unknown Chapman and Kim, 2008; 
Whitton and Feuer, 2004
Shown in the first column are the viruses known to chronically infect humans, their primary nucleic acid type, and an estimate of the prevalence of 
infection in humans. Additional columns list known sites of persistent infection and the diseases associated with infection. When incidence numbers 
are not clearly available worldwide, estimates from the United States are substituted. For many viruses, the specific sites of persistence are incom-
pletely defined. The associated clinical syndromes presented are not an exhaustive list. CNS, central nervous system.were discovered quite recently (Zur, 2008). The initially discov-
ered JC and BK polyomaviruses infect between 72% and 98% 
of humans. It is likely that most humans carry many or all of 
these five viruses and thus harbor chronic polyomavirus infec-
tions in the nervous system, kidney, lung, and skin (Table 1). 
There are many animal polyomaviruses (Zur, 2008), and poly-
omavirus infection is highly species specific. This suggests 
prolonged coevolution of humans with at least five different 
polyomaviruses. Similarly, the eight known human herpesvi-
ruses are extremely efficient at establishing chronic infections; 
most of us carry many herpesviruses for our entire lives (Table 1). New polyomaviruses are not our only recently recognized 
passengers. Anelloviruses and related viruses, as well as 
adeno-associated virus (AAV), are now recognized to infect 
most humans by the end of childhood (Davidson and Shulman, 
2008; Ninomiya et al., 2008; Hino and Miyata, 2007) (Table 1). 
Many human tissues harbor AAV genomes either as integrated 
sequences in genomic DNA or as circular episomes. We pre-
dict that the advent of high-throughput genome sequencing 
will significantly increase the number of known human viruses 
and the number of viruses that contribute to our metagenome 
via the establishment of chronic infection.Cell 138, July 10, 2009 ©2009 Elsevier Inc. 33
Figure 2. Chronic Viral Infections in Humans
The number of humans infected with different chronic viruses is estimated from the percentage of humans carrying a given virus (Table 1), assuming that the 
world population is 6.75 billion. Where available, the lower reasonable estimate of infection prevalence from Table 1 is used. For adenovirus, the situation is 
unclear and the prevalence of chronic infection is arbitrarily set at 1%. For some viruses in Table 1 that contribute to our virome, the prevalence of infection is 
not sufficiently well defined for inclusion in the graph. These include xenotropic murine leukemia virus-related virus (XMLV), human T cell leukemia virus (HTLV 
II, III, IV), and polyomaviruses MC, KI, and WU. The estimates in the graph are approximate as they apply data on prevalence in the limited populations studied 
to date to the global human population.Types of Chronic Viral Infection
Viruses have evolved highly effective strategies for establishing 
chronic infection despite the presence of an active host anti-
viral immune response. Thus, they should be viewed as highly 
sophisticated molecular machines that have been “studying” 
us far longer than we have been studying them. There are three 
general strategies for chronic viral infection: continuous repli-
cation, latency and reactivation, and invasion of the genome 
followed by vertical spread from generation to generation. Indi-
vidual viruses usually rely mostly on one strategy, but viruses 
can utilize more than one mechanism. For example, HIV effec-
tively utilizes both continuous replication and establishment of 
latency (Chun et al., 1997; Finzi et al., 1997; Wong et al., 1997), a 
dangerous combination. The differences between these strat-
egies have profound implications for the immune system and 
for virologists and immunologists designing ways to prevent 
or control harmful chronic viral infections. These differing viral 
strategies expose viral genomes to distinct evolutionary forces, 
resulting in significant molecular differences between viruses 
that persist through different mechanisms.
Continuous Productive Replication
Continuous replication depends on the generation of infectious 
virions despite ongoing antiviral immunity (Figure 3). Viruses 
in this category include HIV, HBV, and HCV in humans, sim-
ian immunodeficiency virus (SIV) in nonhuman primates, and 
lymphocytic choriomeningitis virus (LCMV) in mice. Continu-
ous replication can generate up to 1012 particles per day for 
HBV and HCV (Rehermann and Nascimbeni, 2005). There is 
enormous opportunity for evolution of the virus genome during 
such infections. Viruses that persist via continuous replication 34 Cell 138, July 10, 2009 ©2009 Elsevier Inc.express potentially antigenic viral proteins that are required for 
viral assembly and release, resulting in continuous antigenic 
stimulation of lymphocytes (Figure 3). Continuous replication 
has other effects on the immune system—low levels of tissue 
damage and stimulation of inflammatory cytokines and costim-
ulatory molecules may alter the normal immune system. Some 
viruses, however, are very efficient at avoiding the generation 
of such inflammatory signals. For example, HBV infection can 
proceed for weeks without any significant induction of either 
innate or adaptive immunity in a “stealth” approach to estab-
lishing chronic infection (Wieland and Chisari, 2005).
Latent Infection and Reactivation
Cellular latency (herein termed latency) is neither slow viral 
replication nor the presence of viral nucleic acid without the 
capacity to reactivate. Rather, latency is a unique transcrip-
tional and translational state of a virus in which the produc-
tive replication cycle, and thus the expression of most or all 
antigens, is silent but can reinitiate (Figure 3). Cellular latency 
should not be confused with clinical latency, a term used alter-
nately to describe either the time between infection and signs of 
illness or a host carrying a latent virus. The nature of latency is 
influenced by the virus, the cell infected, and the immunologic 
milieu of the host. There can be several different transcriptional 
forms of latency for a given virus, reflecting different patterns of 
gene and antigen expression. For example, Epstein-Barr virus 
(EBV) utilizes three distinct latency gene expression programs 
(Rickinson and Kieff, 2007; Kieff and Rickinson, 2007). The dif-
ferentiation state of the latently infected cell is an essential vari-
able in latency and reactivation. For example, papillomaviruses 
latently infect epithelial stem cells and initiate different viral 
transcriptional programs as skin cells differentiate and move 
toward the body surface, eventually resulting in shedding of a 
metabolically dead cell-husk filled with infectious virus (Long-
worth and Laimins, 2004).
In contrast to continuously replicating viruses, latent viruses 
retreat from adaptive immunity into a transcriptionally and anti-
genically quiescent state. Perhaps the most frightening example 
of this is HIV, which can survive in memory CD4 T cells in the 
proviral state without expressing any proteins that can be rec-
ognized by the immune system. Similarly, EBV can establish 
latency in memory B cells with undetectable expression of pro-
tein-coding RNAs, at least until the latently infected cell divides 
(Hochberg et al., 2004). There is no known immune mechanism 
to recognize such latent virus-infected cells; these cells can-
not be cleared unless the virus can be 
induced to express antigen. This explains 
the exceptional success of viruses that 
target long-lived cells for latency. Exam-
ples of these cells include neurons (HSV, 
varicella zoster virus or VZV), hematopoi-
etic stem cells (cytomegalovirus or CMV), 
epithelial stem cells (papillomaviruses), 
and memory lymphocytes (HIV, EBV, 
KSHV or Kaposi’s sarcoma associated 
herpesvirus) (Table 1).
The capacity to establish an immu-
nologically silent infection has obvious 
implications for the feasibility of pre-
ventative or therapeutic vaccines. Pre-
venting these infections would require 
either immune blockade of infection 
before establishment of latency or the 
induction of an immune response that 
can both trigger viral emergence from 
latency and eliminate the now-visible 
infected cells (Figure 3). The kinetics of the establishment of 
immunologically silent latency are poorly understood due to 
the complexity of studies of the natural history of infection in 
humans and the difficulty of quantifying latently infected cells 
even using advanced molecular technologies. Rapid establish-
ment of immunologically silent latency, as may occur during 
HIV infection, could make sterilizing immunity impossible to 
attain. The mechanisms responsible for the choice between 
latent versus productive infection and the process of reacti-
vation are poorly understood for many viruses. This restricts 
the consideration of how one might eliminate latently infected 
cells. A better understanding of the viral mechanisms of latent 
infection might provide novel approaches to immune system 
control of such infections.
Figure 3. Processes of Acute and Chronic 
Viral Infection
Viruses use a range of strategies for acute and 
chronic infection. (Top) The strategy used dur-
ing acute infection results in the expression of 
antigens associated with the production of new 
viruses. (Middle) When a virus persists via con-
tinuous productive replication, the same antigens 
expressed during acute infection are produced, 
but the virus has the opportunity to evolve under 
immune selection to produce viruses that express 
neo-antigens and have altered pathogenetic ca-
pacities. (Bottom) In contrast to the previous two 
processes, viruses that persist via latency and 
reactivation can generate antigens associated 
with productive replication but also can enter into 
transcriptional states in which antigens associated 
with latent infection are expressed. In the most 
extreme case, no antigens are expressed, result-
ing in immunological silence. There may be more 
than one latency-associated gene program, and it 
is likely that latency gene programs are cell type 
specific. When these viruses become reactivated, 
they reinitiate a productive replication program 
and once again express viral antigens associated 
with the production of new viruses.Cell 138, July 10, 2009 ©2009 Elsevier Inc. 35
Viruses that establish latency must intermittently reactivate 
to generate new infectious virus for spread within and between 
hosts, thereby generating a wave of antigen. Abortive reacti-
vation occurs frequently for herpesviruses such as EBV and 
murine CMV (Kurz and Reddehase, 1999; Laichalk and Thor-
ley-Lawson, 2005), and perhaps other viruses. In this process, 
viruses express part of the productive replication gene pro-
gram encoding antigens that may activate the immune system, 
but reactivation is aborted before generation of infectious virus. 
Frequent full or abortive reactivation events result in repetitive 
immune stimulation, a situation that may be similar to what is 
observed during continuous replication.
Chronic Infection of the Germline
Mammalian genomes are chronically “infected” by a huge 
number of endogenous retroviral elements (ERVs) that spread 
vertically from one host generation to the next as integrated 
viral genomes or partial genomes in host chromosomes. 
Some ERVs are replication competent, but many are replica-
tion defective. And yet even such defective ERVs can express 
proteins. Human ERVs from over 30 lineages constitute per-
haps 8%–9% of the human genome (Virgin, 2007b). ERVs are 
transcribed in a variety of normal and diseased tissues, and 
they can proliferate within the genome over evolutionary time 
either by production of viruses that reinfect the genome or by 
retrotransposition (Seifarth et al., 2005; Virgin, 2007b).
ERVs can have two effects on the immune system. First, they 
can encode B or T cell antigens (Miyazawa et al., 1987; Wang-
Johanning et al., 2008; Levisetti et al., 2003). Antibodies to such 
an ERV-encoded antigen contribute to spontaneous arteritis in 
the SL/Ni strain of laboratory mice (Miyazawa et al., 1987). An 
antigenic ERV protein is also expressed in non-obese diabetic 
mice concurrent with the development of diabetes (Levisetti 
et al., 2003). Second, ERV-encoded superantigens can shape 
the T cell repertoire (Meylan et al., 2005; Sutkowski et al., 
2001; Stauffer et al., 2001). These superantigens can directly 
stimulate T cells bearing specific forms of the T cell receptor, 
resulting in deletion of the stimulated T cells. Human ERV-K18 
encodes a superantigen that negatively selects specific human 
T cells (Stauffer et al., 2001; Sutkowski et al., 2001; Meylan et 
al., 2005) and whose expression is increased by EBV infection 
or interferon-α (IFN-α) (Sutkowski et al., 2001; Stauffer et al., 
2001). This is a very important point when considering the role 
of chronic virus infection in shaping the human immune sys-
tem. Interactions between chronic viruses, as in the example 
of EBV inducing the expression of an immunoregulatory ERV 
protein, may define the antigen-sensing repertoire of T lym-
phocytes.
Viral Strategies for Chronic Infection
Viruses have evolved a multitude of strategies for evading the 
immune system and persisting in the host. Some rely on the role 
of individual viral genes that have targeted effects on infected 
cells or the immune system itself. Others rely on specific mech-
anisms of tropism and pathogenesis that render the immune 
system ineffective. The location, timing, and magnitude of the 
immune response relative to the speed of virus replication and 
spread is a major determinant of the eventual outcome of viral 
infection (clearance versus establishment of chronic infection) 36 Cell 138, July 10, 2009 ©2009 Elsevier Inc.(Figure 1). This was demonstrated in a recent study visualizing 
both infected cells and antigen-specific T cells in situ during 
the early stages of LCMV and SIV infections (Li et al., 2009).
Viral Tropism and Immune Privilege
Viruses persist in specific cell types during chronic infection, 
a fact with important implications for understanding the failure 
of sterilizing immunity. The viral gene expression program, and 
thus the antigens expressed, may differ from one cell type to 
the next, particularly for ERVs or viruses that persist via latency/
reactivation (Figure 3). For example, the genes expressed by 
EBV in B cells and epithelial cells during chronic infection can 
differ (Rickinson and Kieff, 2007; Kieff and Rickinson, 2007). 
Importantly, surrogate target cells studied in vitro to assess 
immunity or vaccination may not reflect the antigenic dominance 
hierarchy of primary cells infected in vivo. In addition, immune 
effector mechanisms can be more or less effective depend-
ing on the specific cell type. Cell lines used in vitro may not 
reflect these tissue-specific immune interactions. For example, 
murine γ-herpesvirus 68 (MHV-68, γHV68) establishes latency 
in both B cells and macrophages. The cytokine interferon-γ 
(IFN-γ) regulates γHV68 latency and inhibits reactivation in 
macrophages, but it has minimal effects on latent infection of 
B cells (Steed et al., 2007). Furthermore, proteins contained in 
the “lytic” granules of cytotoxic T cells can participate in inhibi-
tion of HSV reactivation from neurons without causing lysis of 
the target cell (Knickelbein et al., 2008). Together, these factors 
complicate extrapolation of in vitro immunologic studies to the 
real situation in tissues during chronic infection.
The cell type specificity of viral and host gene functions con-
tributes to increased efficiency of the immune system in some 
tissues in comparison to others (immunoprivilege). This is an 
important contributor to maintenance of chronic viral infec-
tion. For example, the immune system fails to clear LCMV from 
the kidney or murine γHV68 from the elastic media of the great 
arteries at times when other tissues are efficiently cleared 
(Oldstone et al., 1986; Dal Canto et al., 2001). Immunoprivilege 
likely contributes to HSV persistence in neurons and papillo-
mavirus persistence in epithelial cells. The genitourinary tract 
is a particularly difficult place for the immune system to police 
and can be persistently infected with human T cell leukemia 
virus (HTLV), human cytomegalovirus (HCMV), KSHV, EBV, HIV, 
LCMV, HSV, and polyomaviruses (Virgin, 2007b).
Cell tropism may have other important effects in vivo. For 
example, LCMV clone 13 efficiently establishes persistent 
infection in immunocompetent mice, partially due to its tro-
pism for fibroblastic reticular cells and dendritic cells (Sevilla 
et al., 2004; Mueller et al., 2007). For HIV, different reservoirs 
of latency are cleared with different kinetics by antiviral drugs 
and perhaps the immune system (Chun et al., 1997; Finzi et 
al., 1997; Wong et al., 1997). Chronic viruses commonly tar-
get more than one cell type (Zerboni and Arvin, 2008; Virgin, 
2007b). For example, VZV targets neurons and T lymphocytes, 
EBV targets B lymphocytes and epithelial cells, and HIV targets 
T cells and macrophages. Immune processes that deal with 
HSV reactivation in neurons may be distinct from those that 
control HCV replication in hepatocytes. Therefore a “one size 
fits all” immunologic approach may not be effective in eliminat-
ing or controlling a given persistent infection.
Figure 4. T Cell Functionality during Acute versus Chronic Viral Infection
During viral infection, naive T cells are primed by antigen, costimulation, and inflammation to differentiate into effector T cells. If the infection is cleared and 
antigen and inflammation are eliminated or substantially reduced, some of these functional effector T cells can further differentiate into highly polyfunctional 
memory T cells. These memory T cells are capable of coproducing multiple cytokines (for example, IFN-γ, TNF, IL-2), becoming cytolytic, and proliferating 
vigorously. These cells also have high survival capacity and are maintained for long periods in the absence of antigen. In humans, T cells specific for vaccinia 
virus or the live attenuated yellow fever virus vaccine have these properties. In contrast, during a chronic infection, antigen and inflammation persist following 
the effector phase and these factors can influence T cell function. During some persisting infections, antigen levels may be low and virus-specific CD8 T cells 
that possess multiple functions can develop. These cells might also express low levels of inhibitory molecules such as PD-1. In humans, CMV-specific CD8 T 
cells can sometimes exist in such a state of functionality. As antigen or viral load increases, T cells become less polyfunctional, losing effector functions in a 
hierarchical manner. Expression of inhibitory receptors can increase in this setting. EBV-specific CD8 T cells in humans could be an example of this type of T 
cell. As viral load and antigen increase, T cells become increasingly less functional, occasionally lacking many if not most effector functions. Inhibitory receptor 
expression increases and the susceptibility to apoptosis becomes greater. HIV-, HCV-, and HBV-specific CD8 T cells have been described in these stages of 
dysfunction. Ultimately, if the severity or duration of the infection is high or prolonged, virus-specific T cells can be completely eliminated, leading to the loss 
of virus-specific T cell responses. T cell dysfunction can become progressively worse even during the same infection as the viral load and/or inhibitory signals 
increase. Whereas the dysfunction can be reversed at early stages of exhaustion, it becomes more permanent as exhaustion progresses and the cells become 
more terminally differentiated. (Inset) It is critical to restrain T cell proliferation during chronic infections. In the typical kinetics of a CD8 T cell response to viral 
infection (blue line), the number of antigen-specific T cells peak at approximately one week post-infection before declining. If antigen-driven proliferation is not 
downregulated during persisting infections and T cells continue to divide every ~4–6 hr, the number of antigen-specific T cells would rapidly reach catastrophic 
levels (red line).Viral Evasion and Subversion of Immunity
Because there is a survival advantage for viruses that are shed 
for prolonged periods, it is no surprise that many viruses have 
genes that play a niche-specific role during chronic infection. 
The existence of niche-specific genes that have specialized 
roles during chronic infection is well demonstrated by the 
latency genes of EBV (Rickinson and Kieff, 2007; Kieff and 
Rickinson, 2007), which are specialized to prolong the infec-
tion of memory B cells and to respond to and regulate B cell 
activation and differentiation. These genes perform multiple 
functions, including maintenance of the viral episome, regula-
tion of B cell antigen receptor signaling, and regulation of cell 
cycle and apoptosis. Genes such as the v-cyclin and v-Bcl-2 
of murine γHV68 are also niche specific for chronic infec-
tion, playing a role in reactivation from latency but being less 
important for acute infection (Van Dyk et al., 2003; Loh et al., 
2005). The γ-herpesvirus v-cyclins have evolved the capacity 
to interact with a broader range of cyclin-dependent kinases 
than their closest host homologs (Upton et al., 2005). Similarly, γ-herpesvirus Bcl-2 proteins have evolved to have highly effec-
tive interactions with the host cell death and autophagy path-
ways that are not subject to normal host cell regulatory mecha-
nisms (Loh et al., 2005; Wei et al., 2008). These are examples 
of the type of niche-specific adaptation fostered by prolonged 
coevolution of virus and host.
Viruses encode a broad array of genes that enable them 
to evade immunity during acute or chronic infection (Virgin, 
2007b). These genes may contribute to the establishment 
of chronic infection by preventing the clearance of acute or 
chronic infection (Figure 1). Viral immune evasion genes can 
act by (1) decreasing expression of molecules required for T 
cell or natural killer (NK) cell recognition, (2) inhibiting antigen 
presentation, (3) acting as agonists or antagonists of cytok-
ines and chemokines, and (4) blocking intracellular antiviral 
or proinflammatory effects of interferons or other cytokines. 
NK cells and IFN-αβ, usually thought of as important during 
acute infection, can influence latent and persistent infection by 
herpesviruses (Barton et al., 2005; Steed et al., 2007; Biron et Cell 138, July 10, 2009 ©2009 Elsevier Inc. 37
Figure 5. T and B Cell Responses during Acute and Chronic Infection
Following acute viral infection, T cell responses are generated and play a role in the control of initial viral replication. (Top left) After the clearance of infection, T 
cells form a pool of stable, highly polyfunctional memory T cells that can persist long-term via self-renewal in the absence of antigen. (Top right) The B cell re-
sponse following an acute viral infection is characterized by the initial generation of short-lived plasma cells that contribute to an early phase of serum antibody 
production. After clearance of the virus, memory B cells and long-lived plasma cells from the germinal center are generated. Long-lived plasma cells home to 
the bone marrow and constitutively produce immunoglobulins that maintain circulating serum antibody levels for long periods. Memory B cells are maintained 
and can give rise to plasma cells upon reactivation. (Bottom left) During chronic viral infection, T cell responses are also generated and can persist over time. 
However, these virus-specific T cells generated during chronic infection are subject to negative regulation, lose polyfunctionality, and become antigen depen-
dent rather than developing the ability to persist long-term via antigen-independent self-renewal. (Bottom right) Although less is known about the dynamics of 
B cell responses during chronic viral infection than about T cell responses, serum antibody and plasma cells are clearly generated during persisting infections. 
It is not clear whether the plasma cell populations generated during chronic viral infections have the same characteristics as those formed following clearance 
of acute infection. In addition, memory B cells might be formed during chronic viral infection, but the continuous presence of antigen could drive these memory 
B cells toward becoming short- or long-lived plasma cells.al., 1989). It will be important to determine which viral immune 
evasion genes are critical for persistence in vivo so that these 
genes can be specifically targeted for pharmacologic interven-
tion or vaccination.
Mutation and Selection of Viral Variants
The error-prone RNA polymerases of viruses such as HCV 
and HIV are major contributors to chronic infection via the 
generation of quasispecies—swarms of viruses with different 
sequences—that can evade the immune system or develop 
new pathogenetic properties (for example, see Pfeiffer and 
Kirkegaard, 2005). In addition to point mutations, duplica-
tions, deletions, recombination events, and even genomic 
acquisition of host mRNAs have occurred in different viruses. 
Perhaps best studied of these are immune escape virus 
mutants, which have a well-established role in evading adap-
tive immune responses (for examples, see Pircher et al., 1990; 
Bowen and Walker, 2005). During HCV, HIV, or SIV infection, 
these mutations accumulate in CD8 T cell epitopes, a pro-
cess associated with disease progression and viral escape 
from vaccine and T cell-mediated control (Bailey et al., 2004; 
Bowen and Walker, 2005). Immune escape mutations in viral 
proteins have been found that inhibit multiple steps in antigen 
presentation, including proteasomal generation of peptide, 38 Cell 138, July 10, 2009 ©2009 Elsevier Inc.binding of peptides to MHC class I molecules, and recogni-
tion of peptide:MHC complexes by the T cell receptor (Bowen 
and Walker, 2005).
Immune Responses during Chronic Viral Infection
The viral strategies described above for the maintenance of 
chronic infection are balanced by the effects of the virus-
specific immune response, thereby establishing a metastable 
equilibrium between host and pathogen. It is well established 
that there is a complex regulatory network that actively inhibits 
immune responses during chronic viral infections. This regu-
lation of the immune response is essential for two main rea-
sons. The first reason is to reduce excessive immunopathol-
ogy. This is particularly important for the CD8 T cell response 
that can cause massive tissue damage by killing infected cells 
and releasing inflammatory cytokines. Thus, it is not surprising 
that cytotoxicity and the production of cytokines such as tumor 
necrosis factor (TNF) are tightly regulated during chronic infec-
tions, and that these functions are often reduced or lost in CD8 
T cells responding to persistent viruses (Figure 4). The second 
reason is to regulate the extraordinary proliferative potential 
of virus-specific T cells. During the acute phase of infection, 
virus-specific T cells can double in number every 4–6 hr and 
undergo 3–4 doublings per day (Murali-Krishna et al., 1998; 
Miller et al., 2008). This translates into a 10-fold increase per 
day. If this level of proliferation were to continue unchecked, 
one would have astronomical (and potentially catastrophic) 
numbers of virus-specific T cells within a very short time (Fig-
ure 4, inset). It is essential to put brakes on this remarkable pro-
liferative capacity. In fact, a hallmark of virus-specific T cells 
during chronic infections is a greatly reduced ability to prolifer-
ate in response to antigen.
It is important to emphasize that despite this diminished pro-
liferative capacity and a decrease in some effector functions 
(described below), virus-specific T cells play a crucial role in 
controlling viral replication and thereby keeping our virome in 
check. For example, this is true for EBV and HCMV infections, 
as well as for HIV infection in “elite” controllers. Elite controllers 
are a unique subset of HIV-infected individuals who are able 
to limit HIV infection to a very low level for long periods. How-
ever, during progressive HIV, HCV, or HBV infection, T cell dys-
function can become so profound that the T cells are unable 
to effectively control viral replication. Thus, there are varying 
degrees of function and dysfunction in T cells during persis-
tent infections (Figures 1 and 4). A better understanding of the 
mechanisms responsible for progressive T cell dysfunction 
during chronic infection may allow us to develop immunologi-
cal and vaccine approaches that reduce the disease burden of 
some of these intractable chronic infections in humans.
T Cell Responses
In considering the nature of T cell responses during chronic 
infection, it is useful to start with understanding the responses 
to acute infection. Memory CD8 and CD4 T cell differentiation 
following acute viral infections results in the formation of high-
quality, long-lived memory cells (Kaech and Wherry, 2007). 
These T cells have several cardinal properties that allow them 
to confer protective immunity. Chief among these properties is 
the ability to persist long-term in the absence of antigen and to 
respond rapidly upon re-exposure to the pathogen. This recall 
response is characterized by rapid elaboration of effector func-
tions such as cytotoxicity and cytokine/chemokine production, 
proliferation accompanied with substantial increases in T cell 
numbers, and migration of effector T cells to sites of infection.
The differentiation of robust memory T cells after acute 
infection follows a general program, with the critical memory 
properties developing gradually over time. Both the strength 
of antigen stimulation and inflammation can impact the kinet-
ics or pattern of this differentiation. For example, inflamma-
tion is essential for effective activation of naive T cells and 
generation of effector and memory T cells, but higher levels 
of inflammation can foster the generation of more terminally 
differentiated effector T cells (Mescher et al., 2006; Joshi et 
al., 2007). The tissue microenvironment can also, perhaps via 
virus-dependent local inflammatory signals, affect the capac-
ity of T cells to produce the cytokine interleukin-2 (IL-2), alter 
homing properties (Mora et al., 2003), change memory T cell 
phenotype (Marzo et al., 2007), and define the overall pattern of 
memory T cell differentiation (Masopust et al., 2006). If the pri-
mary immune response clears the infection (Figure 1), some T 
cells will differentiate into long-lived memory T cells (Figure 5). 
In fact, the ability to respond efficiently to homeostatic signals such as IL-7 and IL-15 and undergo homeostatic self-renewal is 
a property that is only acquired by memory T cells that develop 
in the absence of antigen.
Many of the key properties of effective memory T cells 
develop after the clearance of antigen and inflammation fol-
lowing acute infection. During chronic viral infections, where 
antigen and/or inflammation persist, antiviral T cell responses 
can differ dramatically. In addition, virus-specific CD4 and 
CD8 T cells often exhibit various stages of exhaustion (Figures 
4 and 5) (Shin and Wherry, 2007; Klenerman and Hill, 2005). 
Exhaustion-associated T cell defects range from loss of effec-
tor functions to failure to exhibit antigen-independent homeo-
static proliferation. CD8 T cell exhaustion was first described 
during LCMV infection of mice where virus-specific CD8 T cells 
initially developed effector functions such as cytokine produc-
tion and cytotoxicity but lost these properties as the chronic 
infection progressed (Zajac et al., 1998; Wherry et al., 2003, 
2007). This loss of function is hierarchical (Figure 4), with some 
functions exhausted early or in the presence of low viral load 
(for example, IL-2 production, cytotoxicity, proliferation) and 
others (e.g., IFN-γ production) persisting longer (Zajac et al., 
1998; Wherry et al., 2003). Eventually, especially if viral load is 
high or if help from CD4 T cells is lacking, virus-specific CD8 T 
cells deficient for most effector functions (for example, ex vivo 
cytotoxic activity, production of IL-2, TNF, and IFN-γ) are found 
(Zajac et al., 1998; Wherry et al., 2003). In the extreme situa-
tion, exhausted CD8 T cells can be physically deleted (Zajac 
et al., 1998; Moskophidis et al., 1993; Wherry et al., 2003). The 
severity of T cell dysfunction during chronic infection corre-
lates directly with the level of infection and expression of inhibi-
tory receptors by virus-specific T cells and correlates inversely 
with help from CD4 T cells. Similar types of T cells have been 
described in many experimental models, and dysfunctional 
virus-specific CD8 T cells have also been described during 
human chronic infections (Shin and Wherry, 2007; Klenerman 
and Hill, 2005).
Defects in memory T cell differentiation during chronic viral 
infections are not just confined to effector functions. They also 
include a failure to develop into self-renewing antigen-inde-
pendent memory T cells (Shin and Wherry, 2007). Reduced 
expression of IL-7 and IL-15 receptors, and an inability to effec-
tively respond to these cytokines, results in defective antigen-
independent homeostatic self-renewal (Shin and Wherry, 
2007). These virus-specific CD8 T cells require cognate anti-
gen, instead of IL-7 and IL-15, for maintenance (Shin et al., 
2007). The failure to undergo IL-7- and IL-15-driven antigen-
independent maintenance leads to a loss of virus-specific CD8 
T cells if the antigen is removed. In this situation, changes in 
antigen expression due to antiviral therapy or generation of 
neoepitopes by viral mutants may result in the loss of these 
“antigen-addicted” CD8 T cells with important consequences 
for viral re-emergence or reinfection.
B Cell Responses
The fundamental nature of the B cell response is also altered 
by chronic infection. Antiviral B cell responses following acute 
viral infection occur in a series of stages (Figure 5). Initial B cell 
activation results in the generation of a population of short-
lived antibody-producing cells and a population of activated Cell 138, July 10, 2009 ©2009 Elsevier Inc. 39
B cells that enter the germinal center reaction. The short-lived 
antibody-producing cells provide an initial burst of usually low-
affinity antibody (Hangartner et al., 2006; Ahmed and Gray, 
1996) that can limit the spread of virus and blunt the infection 
until higher-affinity antibody-producing cells emerge from the 
germinal center (Hangartner et al., 2006). In the germinal cen-
ter, in addition to affinity maturation and isotype switching, B 
cells begin differentiation along one of two possible lineages 
(Calame et al., 2003). Some B cells emerge as memory B cells 
that are capable of long-term persistence and endowed with the 
capacity to respond vigorously upon reinfection. Other germi-
nal center B cells differentiate into long-lived plasma cells that 
home to the bone marrow and some mucosal sites where they 
constitutively produce copious amounts of antibody. These 
cells can persist for months to years in the absence of antigen 
(Slifka et al., 1998; Manz et al., 1997) and are responsible for 
the prolonged maintenance of antiviral antibodies observed in 
humans for decades in the absence of viral reinfection (Ham-
marlund et al., 2003; Crotty et al., 2003)
Although there is considerably more known about exhaus-
tion and dysfunction of T cells during chronic viral infection, 
several recent studies indicate that B cells may also be nega-
tively impacted in these settings. A recent study has defined 
B cell exhaustion during HIV infection (Moir et al., 2008). This 
study shows that HIV-specific B cells, but not B cells spe-
cific for other antigens, have a low proliferative capacity and 
express Fc-receptor-like-4 (FCRL4) that can generate signals 
that inhibit B cell function. In addition, there is also evidence 
that the inhibitory coreceptor programmed death 1 (PD-1) 
influences B cell responses during chronic SIV infection as in 
Figure 6. Immunoregulatory Pathways Inhibit Antiviral T Cell Func-
tion during Chronic Viral Infection
Four distinct classes of events could limit T cell responses to persisting vi-
ruses. First, T cell intrinsic expression of inhibitory receptors such as PD-1, 
CTLA-4, LAG-3, and others can negatively regulate T cell function and limit 
the effectiveness of antiviral activity. Second, immunoregulatory cytokines 
such as IL-10, TGF-β, and possibly additional factors produced by other cells 
in the environment can modulate and suppress vigorous antiviral T cell re-
sponses. Third, regulatory cells can modulate antiviral effector T cells. These 
regulatory cells could include traditional FoxP3+ natural or adaptive CD4+ T 
regulatory cells (Tregs), regulatory CD8 T cells, or myeloid suppressor cells. 
Finally, changes in antigen-presenting cell (APC) usage or function could im-
pact virus-specific CD8 T cells. The quality of T cell stimulation can also be 
impacted by changes in dendritic cell function or number, as well as differ-
ences in antigen presentation by professional versus nonprofessional APC 
during persisting viral infection.40 Cell 138, July 10, 2009 ©2009 Elsevier Inc.vivo blockade of this pathway enhances the SIV-specific anti-
body response in primates (Velu et al., 2008). Further, a high 
ratio of antigen to antigen-specific B cells can lead to termi-
nal differentiation of B cells and ultimately loss of effective 
IgG responses (Zellweger et al., 2006). It has also long been 
known that alterations in B cell responses, B cell tolerance, 
and the accumulation of antibody-antigen immune complexes 
are associated with chronic viral infections and can contribute 
to disease (Casali and Oldstone, 1983). These observations 
are consistent with the data on T cell exhaustion described 
above and suggest that B cells are also likely to be negatively 
influenced by persisting viral infection. Future studies address-
ing the differentiation pattern of virus-specific B cells during 
chronic viral infections, the mechanisms of B cell dysfunction, 
and the role of CD4 T cell exhaustion in this process should be 
informative.
Mechanisms Regulating Immunity during Chronic 
Infections
Several mechanisms regulate immune responses during 
chronic viral infection (Figure 6). These include inhibitory recep-
tors on T cells, altered APC, immunoregulatory cytokines, and 
regulatory T cells (Tregs). These mechanisms can work in con-
cert to limit immunopathology. However, this dampening of T 
cell function may also prevent the immune system from clear-
ing the infection.
Inhibitory Receptors on T Cells
Upregulation of inhibitory receptors by exhausted CD8 T cells 
is an important mechanism of T cell dysfunction during chronic 
viral infections. The inhibitory receptor PD-1, a CD28 fam-
ily costimulatory/coinhibitory molecule, regulates CD8 T cell 
exhaustion during chronic LCMV infection in mice (Barber et 
al., 2006; Wherry et al., 2007). PD-1 is highly overexpressed by 
virus-specific exhausted CD8 T cells in comparison to func-
tional memory CD8 T cells. Notably, blockade of the PD-1:PD-1 
ligand (PD-L) pathway during chronic LCMV infection leads to 
the recovery of T cell function and reduced viral load (Barber et 
al., 2006). This is a fundamentally important observation show-
ing that some changes in CD8 T cells during chronic infection 
are reversible. These results have been extended to humans 
where the PD-1:PD-L pathway regulates HIV-, HBV-, and HCV-
specific T cells in vitro (Sharpe et al., 2007). In vivo studies in 
the primate SIV model also demonstrate the importance of the 
PD-1 pathway, as PD-1 blockade improves T cell (and B cell) 
responses, lowers viral load, and extends life span in chroni-
cally infected animals (Velu et al., 2008).
A key question is whether PD-1:PD-L blockade reprograms 
the entire T cell population or only a subset of dysfunctional T 
cells. Recent work suggests that only a subset of exhausted 
CD8 T cells responds effectively to PD-1:PD-L blockade in 
vivo (Blackburn et al., 2008). Surprisingly, the responsive sub-
set expresses intermediate levels of PD-1 (PD-1Int), whereas 
the subset that could not be rescued expresses the highest 
levels of PD-1 (PD-1Hi) (Blackburn et al., 2008). Furthermore, 
these two subsets of exhausted CD8 T cells are found in dif-
ferent anatomical locations in mice (Blackburn et al., 2008). 
Similarly, circulating HCV-specific CD8 T cells in humans are 
PD-1Lo/Int, whereas those in the liver are PD-1Hi (Nakamoto et 
Figure 7. Differences between T Cell Anergy and T Cell Exhaustion
Anergy is a type of T cell dysfunction in which T cells are initially primed improperly by signaling (red lightning bolt) through the T cell receptor (TCR) in the 
absence of costimulatory or inflammatory signals. Such anergized T cells fail to develop proper function from the outset and are refractory to subsequent TCR 
stimulation. In contrast, exhausted T cells are primed by antigen (red lightning bolt), costimulation, and inflammation. These T cells initially develop effector 
functions, but prolonged (and perhaps excessive) stimulation leads to progressive loss of function over time. They eventually exhibit a poor responsiveness 
to antigen. In agreement with these distinct modes of induction of T cell anergy versus exhaustion, there are also key molecular differences between T cells 
exhibiting these two distinct types of dysfunction.al., 2008). Only circulating PD-1Lo/Int HCV-specific CD8 T cells 
respond to PD-1 pathway blockade in vitro (Nakamoto et al., 
2008). The issue of how to manipulate the immune system in 
different tissue environments has not been studied in sufficient 
detail, emphasizing the importance of correctly selecting rele-
vant clinical samples for assessment of the efficacy of immune 
interventions during chronic viral infection.
One possible reason for the poor responses of PD-1Hi 
exhausted CD8 T cells is the coexpression of additional inhibi-
tory receptors such as LAG-3, CTLA-4, 2B4/CD244, CD160, 
GP49, and PirB on the cells (Figure 6) (Blackburn et al., 2009). 
In fact, simultaneous blockade of multiple inhibitory receptors 
substantially improves reversal of exhaustion in comparison 
to PD-1 blockade alone (Blackburn et al., 2009). Recent stud-
ies in humans also demonstrate PD-1 and CTLA-4 coexpres-
sion on some HIV-specific CD4 T cells (Kaufmann et al., 2007). 
These observations indicate that multiple inhibitory receptor 
pathways can cooperate to restrain optimal T cell responses 
during chronic infections. It will be important to define patterns 
of inhibitory receptor coexpression during different chronic 
infections and to delineate the precise T cell properties and 
pathways regulated by diverse inhibitory receptors. Using this 
knowledge, it might be possible to augment beneficial T cell 
functions without enhancing immunopathology.
T Cell Anergy versus Exhaustion
T cell dysfunction that occurs during chronic viral infections 
is distinct from the previously described state of T cell anergy 
(Figure 7). One fundamental difference between anergy and 
exhaustion is the differing mechanisms of induction of these 
types of T cell dysfunction. Anergy is induced when T cells do 
not receive all the necessary signals for T cell activation (for example, the cells receive TCR stimulation but no costimula-
tion) and therefore fail to develop into functional effector cells. 
In contrast, T cell exhaustion during chronic viral infection is 
associated with initially normal effector differentiation followed 
by a progressive loss of function over time. The molecular 
signature of T cell exhaustion reveals pervasive changes in 
transcription in comparison to functional T cells (Wherry et al., 
2007), including overexpression of inhibitory receptors, altered 
expression of transcription factors, changes in signal trans-
duction, and downregulation of key metabolic genes (Table 
2). These transcriptional changes are not the same as those 
observed in anergic T cells, confirming that T cell exhaustion 
and anergy are indeed distinct processes (Wherry et al., 2007). 
Whereas exhaustion is the major type of T cell dysfunction dur-
ing chronic viral infection, anergy may play a role when viruses 
utilize genetic strategies that directly inhibit costimulatory 
pathways in APC.
Regulatory T Cells
There is emerging evidence for a role of regulatory T cells 
(Tregs) (Belkaid and Rouse, 2005) in the equilibrium estab-
lished during chronic viral infection. Foxp3+CD4+ Tregs can 
negatively regulate effective immunity during acute herpesvi-
rus infections (Fernandez et al., 2008; Suvas et al., 2003). Para-
doxically, Tregs can also facilitate effective immunity during the 
early stages of acute infection by modulating effector T cell 
recruitment to infected sites (Lund et al., 2008). However, Tregs 
are more often associated with ineffective immune responses 
during chronic infections, including those by Friend leukemia 
virus (Zelinskyy et al., 2006), HIV (Kinter et al., 2007; Nilsson 
et al., 2006), HCV (Boettler et al., 2005; Ebinuma et al., 2008; 
MacDonald et al., 2002), and HBV (Franzese et al., 2005; Xu et Cell 138, July 10, 2009 ©2009 Elsevier Inc. 41
Table 2. Cell-Intrinsic Mechanisms of T Cell Exhaustion during Chronic Viral Infection
Type of Defect Examples Potential Consequence
Overexpressed inhibitory 
receptors
Overexpression of PD-1, LAG-3 e.g., Inhibition of T cell responses, reduced TCR signaling, lim-
ited effector functions and proliferation
Signaling Altered expression of LCK, NFATc, IL-7R e.g., altered TCR and cytokine receptor signal transduction
Altered chemotaxis, homing, 
and adhesion
Increased expression of CCR5, CCL5, CCL3, 
decreased expression of several integrins 
e.g., enhanced inflammatory cell recruitment, altered  adhesion
Changes in transcription factor 
expression
PBX3, Blimp-1, Eomes e.g., altered differentiation state
Metabolic deficiencies Reduced expression of mRNAs encoding ribo-
somal subunits, citric acid cycle enzymes
e.g., reduced energy metabolism, defects in protein  translation
Different types of cell-intrinsic changes occur in lymphocytes during exhaustion. These are listed here with specific examples of the defects and their 
potential consequences. PD-1, programmed death 1; LAG-3, lymphocyte activation gene 3; LCK, leukocyte-specific protein tyrosine kinase; NFATc, 
nuclear factor of activated T cell c; CCR, chemokine (C-C motif) receptor; CCL, chemokine (C-C motif) ligand; PBX3, pre-B cell leukemia homeobox 
3; Blimp-1, B lymphocyte induced maturation protein 1; Eomes, Eomesodermin. This table is adapted from Wherry et al., 2007.al., 2006). Precisely how Treg cells influence viral infection is 
not well understood. These cells could act through cell-to-cell 
contact, inhibition of APC maturation, production of immuno-
regulatory cytokines, or direct inhibition of CD8 T cell effector 
function. Treg cells that limit effective viral control could lead 
to prolonged antigen expression and secondary T cell exhaus-
tion, indicating the potential for synergy between mechanisms 
that inhibit T cell effectiveness during chronic viral infection. 
Enhancing immune control of chronic viral infection likely will 
require that multiple pathways are targeted at the same time.
Immunoregulatory Cytokines
Immunoregulatory cytokines modulate immune responses to 
viral infection and may be interrelated with Treg function. For 
example, when the IL-10 pathway was blocked, virus-specific 
CD8 T cell responses to chronic infection with LCMV were 
enhanced (Ejrnaes et al., 2006; Brooks et al., 2006). The cel-
lular source of this IL-10 remains under debate, and it will be 
important to identify the source and mechanism of the regula-
tion of IL-10 production during chronic infection. In addition to 
IL-10, other suppressive or regulatory cytokines such as trans-
forming growth factor β (TGF-β) can impact immune responses 
during persisting infections (Alatrakchi et al., 2007). Although 
these, and likely other, immunomodulatory cytokines impact 
immunity during chronic infections, the mechanisms respon-
sible for these effects are largely unknown. IL-10 and TGF-β 
both can alter the functions of APC and innate immune effector 
cells such as macrophages. These effects could provide a sig-
nificant imprint of chronic viral infection on the immune system 
in general with consequences for responses to self or foreign 
antigens (see below).
Immunologic Imprint of Chronic Viral Infection
What are the consequences to the host of the dynamic but 
metastable equilibrium that is established between virome and 
host during chronic infection? One obvious consequence is 
the development of severe disease during progressive chronic 
infection by viruses such as HIV and HCV, and the less fre-
quent development of severe disease during chronic EBV or 
HSV infection. Aside from directly causing disease, are there 
additional fundamental consequences of chronic viral infec-
tion? As a first step to addressing this question, the nature and 
the level of activity of the immune system during chronic viral 42 Cell 138, July 10, 2009 ©2009 Elsevier Inc.infection must be considered. All chronic virus infections are 
under continuous immune surveillance. Viruses such as CMV, 
polyomaviruses, and EBV cause more and different diseases in 
immunosuppressed patients in comparison to individuals with 
a functioning immune system, indicating that immunity in nor-
mal individuals contains these viruses (Table 1). This concept 
is supported by studies showing that herpesvirus infection is 
associated with ongoing B and T cell activation at mucosal sur-
faces where reactivation occurs (Zhu et al., 2007; Hislop et al., 
2005). These responses are present in the absence of overt 
disease and thus impact the immune system in apparently nor-
mal hosts.
The scope and impact of continuous immune surveillance 
of chronic viral infection should not be underestimated. Reac-
tivation of HSV-2 in the genitourinary system is extremely fre-
quent even in asymptomatic persons (Wald et al., 2000), and 
thus the attendant chronic T cell response in this tissue (Zhu 
et al., 2007) might reasonably be expected to have significant 
effects on mucosal immunity at this site. Even asymptomatic 
viruses such as anelloviruses are under continuous immune 
surveillance (Davidson and Shulman, 2008; Ninomiya et al., 
2008; Hino and Miyata, 2007) (Table 1). It has been estimated 
that over 90% of anelloviruses in serum are replaced daily with 
over a billion new virions, suggesting that significant antigen 
expression may occur for years after the acquisition of infec-
tion in the first years of life. This immune system dynamism 
might be neutral for the host, but we argue that it has a critically 
important role—through changes in tissue cytokines and in B 
and T cells—in defining the “normal” human immune system. 
This “immunologic imprint” of chronic viral infection may fun-
damentally alter the response of the host to new infections, 
vaccines, or neo-epitopes that emerge during immune selec-
tion of viral variants.
Virome Effects on Innate Immunity
Ongoing immune responses to chronic viral infection strongly 
affect innate immunity through the actions of cytokines 
released during chronic stimulation of T cells and possibly NK 
cells. This may be particularly important for viruses harbored 
in lymphoid tissues during chronic infection (Table 1) where the 
bystander effects of cytokines might be expected to have spe-
cial importance. Stimulation of freshly explanted CD4 or CD8 T 
cells with CMV peptides induces rapid secretion of cytokines 
IFN-γ, TNF-α, and MIP1-β, indicating that cells primed to rap-
idly respond to viral antigen continuously circulate through the 
body (Sester et al., 2002; Casazza et al., 2006). Similar find-
ings have been reported for EBV-specific CD4 and CD8 T cells 
(Hislop et al., 2005). Importantly EBV-specific T cells represent 
up to 20% of the total CD8 T cells in the noninflamed tonsils of 
long-term EBV carriers (Hislop et al., 2005). This is an anatomic 
site at which prolonged virus shedding occurs and stimulates 
these T cells (Hislop et al., 2005). Given the high level of chronic 
herpesvirus infection in the population (Table 1), and evidence 
for continuous shedding of herpesviruses at mucosal sites 
with attendant antigen expression and T cell activation, it is 
reasonable to conclude that mucosal production of powerful 
cytokines is frequent in most normal humans. This has obvious 
potential importance for regulating mucosal barrier function or 
in the case of HIV, which replicates in activated lymphocytes, 
for enhancing infection.
New evidence in animals indicates that chronic virus infection 
can fundamentally alter innate immunity to nonviral pathogens. 
IFN-γ expression during herpesvirus latency can symbiotically 
protect the host from infection by the bacteria Listeria mono-
cytogenes and Yersinia pestis, the causative agent of plague 
(Barton et al., 2007). Thus, the détente developed between 
herpesviruses and their hosts over tens of millions of years of 
coevolution may offer benefits to the host. This protection may 
come at the cost of enhanced autoimmunity (Peacock et al., 
2003). In addition, the prolonged presence of Sendai virus viral 
nucleic acids in mice is associated with IL-13-dependent NKT 
cell activation that can, in turn, contribute to reactive airway 
disease (Kim et al., 2008). Further, abnormal interferon secre-
tion by plasmacytoid dendritic cells predisposes to secondary 
infection during chronic LCMV infection (Zuniga et al., 2008). 
It has been proposed that chronic activation of innate immune 
responses contributes to immune dysfunction in HIV and SIV 
infection (Mandl et al., 2008). Together, these examples pro-
vide a convincing case for a significant immunologic imprint of 
chronic viral infection on the nature of innate immune responses. 
Much remains to be done to define the balance between immu-
nologic benefit and immunologic harm for chronic infection of 
humans by viruses that seldom cause overt disease.
Because responses to our virome imprint the immune sys-
tem, studies in mice that lack chronic infections may sacrifice 
relevance for ease of experimentation. Most experimental 
animals are not chronically infected with relevant viruses, but 
humans carry many chronic viral infections (Table 1, Figure 
2). Thus, it is possible that differences between human and 
murine immune responses reflect the immunologic imprint of 
our virome rather than inherent differences in immunity. This 
has implications for how data from animals raised in virus-free 
barrier facilities are used to define mechanisms of immunity 
and to validate vaccine approaches to be applied in hosts with 
multiple chronic infections. Studies of immunologic mecha-
nisms are clearly easier when confounding effects of concur-
rent infection are removed, but the immune system does not 
exist in a vacuum. Studies in multiply infected animals whose 
immune systems are subject to chronic activation and the con-
sequent imprint of chronic infection should be compared with 
studies in standard laboratory animals.Virome Effects on Adaptive Immunity
There is significant crosstalk between chronic viral infections, 
as well as between viral infections and other types of infection. 
For example, HIV and HCV coinfection worsens the prognosis 
of both infections (De et al., 2002; Greub et al., 2000). HCV-
dependent worsening of HIV disease progression (De et al., 
2002; Greub et al., 2000), though controversial (Sulkowski et 
al., 2002), is interesting because HCV does not cause overt 
immunosuppression. The impact of persisting infections is 
not always negative. For example, infection by herpesviruses 
(HHV-6 or HHV-7) or GB virus C may inhibit HIV progression in 
some settings (Grivel et al., 2001; Lisco et al., 2007; Xiang et al., 
2001; Tillmann et al., 2001). The mechanisms responsible for 
such complex interactions remain poorly defined.
The effect of chronic virus infection extends beyond altera-
tions in the biology of antigen-specific T cells responding to 
viral antigens. There is considerable compression of the T 
cell repertoire in chronically infected animals. The ongoing 
response to HSV and CMV is so robust that the proportion of T 
cells specific for these viruses increases over time to the point 
that diminished responses to new antigens may contribute to 
the progressive decrease in immune system responsiveness 
as we age (Nikolich-Zugich, 2008). Further, studies of sequen-
tial virus infection reveal potentially relevant crossreaction 
between viruses such as EBV and influenza A virus (Selin et 
al., 2006). During chronic viral infection, crossreactivity could 
be a double-edged sword if crossreactive T cells become dys-
functional due to exhaustion or inhibition by Tregs. In addition, 
prior virus infection can alter the T cell cytokine response to 
subsequent infections by different viruses; prior immunity to 
one virus can markedly alter vaccine responses to a second 
virus (Selin et al., 2006). Together, these observations provide 
a strong basis for considering that chronic virus infection may 
strongly imprint the adaptive immune response.
The imprint of the cytokine environment created by chronic 
viral infection on adaptive responses to new pathogens is more 
speculative. However, T cells require inflammatory signals for 
full activation and differentiation into effector and memory T 
cells (Curtsinger et al., 1999). In vivo studies have confirmed 
the important role of inflammatory cytokines (including IL-12 
and IFN-αβ) in T cell activation and differentiation (Kolumam 
et al., 2005). IFN-γ has also been implicated in modulating 
the differentiation of memory CD8 and CD4 T cells (Whitmire 
et al., 2005). In addition to influencing CD8 T cell activation 
and expansion (Mescher et al., 2006), IL-12, IFN-αβ, and other 
inflammatory signals shape T cell memory. Priming CD8 T 
cells in vivo in the absence of inflammation results in blunted 
effector T cell responses but more rapid generation of mem-
ory T cells (Pearce and Shen, 2007; Badovinac et al., 2005). 
In addition, increased levels of inflammation can lead to the 
generation of terminally differentiated effector T cells (Joshi et 
al., 2007; Sarkar et al., 2008). Thus, inflammation has a critical 
role in adaptive immune T cell activation and differentiation. 
It is plausible that prolonged inflammation, secondary to the 
immunologic imprint of our virome, can skew T cell responses 
toward more effector T cells and fewer memory precursors, 
generating a long-lasting impact on the quality of the memory 
T cell population.Cell 138, July 10, 2009 ©2009 Elsevier Inc. 43
Redefining Chronic Viral Infection
Recognizing that chronic viruses are contributors to our normal 
metagenome has two highly interrelated and fundamentally 
important consequences. First, we need to reformulate how 
we attribute disease to specific viruses and how genome-wide 
association studies are performed in humans. Second, we 
need to recognize that our normal immune system is subject 
to the imprint of the dynamic equilibrium between our genome 
and the endogenous virome.
Virome as Part of the Metagenome: The Implications
What implications does the presence of an internal virome that 
is in a dynamic equilibrium with our immune system have for 
human disease? Classically, a virus is considered to a potential 
cause of disease when it is present in persons with disease 
and absent from persons without disease. Recent findings 
suggest that this simple approach does not capture the entire 
role of viruses in disease, indicating the need to reformulate 
our criteria for disease causality during chronic viral infec-
tion. Even viruses of low virulence occasionally cause severe 
illness in apparently normal people—a phenomenon that has 
been attributed to stochastic events, human genetics, viral 
dose, viral variants, or transient immunosuppression. Although 
each of these explanations may apply, a sea-change in how 
we define viral infection is being driven by a combination of 
classical genetics and the genomic revolution (Bustamante et 
al., 2008). In this emerging view, the well-known role of host 
genetic variation comes to the fore because highly specific 
allelic polymorphisms or mutations predispose a limited num-
ber of individuals to diseases caused by viruses that otherwise 
only rarely cause overt disease. In a real sense, the genes in 
the host “cause” the disease, as the viruses can infect many 
but cause disease in only a few.
The key factors in this emerging formulation are (1) new esti-
mates of the number of genes that confer susceptibility to a 
given virus and (2) the exquisite specificity of some alleles for 
certain viruses. Random mutagenesis of the mouse genome 
suggests that there are about 300 genes that determine resis-
tance to murine CMV (Beutler et al., 2006). Furthermore, sets 
of genes can act in a combinatorial fashion to confer viral 
resistance. For example, interactions between killer inhibi-
tory (KIR) alleles encoding NK cell receptors and MHC class I 
alleles contribute to susceptibility to HIV, HCV, and EBV infec-
tion (Khakoo et al., 2004). There are many allelic variations that 
influence chronic viral infection (Virgin, 2007b). These include 
CCR5 variations that affect infection by HIV, HLA variations 
that affect development of cervical cancer and infection by 
papillomavirus, HIV, HBV, and HCV, CXCR4 variations and 
the development of warts, EVR1 and EVR2 variations and the 
development of papillomavirus-induced epidermodysplasia 
verruciformis, and complement gene variations that affect HBV 
vaccine responsiveness. Furthermore, the effects of allelic 
variation in genes, alone or in combination, can be highly spe-
cific for a given infection. For example, deficiency in the innate 
immune-signaling molecules MyD88 or IRAK-4 is associated 
with severe pyogenic bacterial infection, but patients appear 
to have normal resistance to viral infections (von Bernuth et al., 
2008; Ku et al., 2007). In contrast, mutations in UNC93B1 and 
TLR3, two proteins involved in innate immune responses to 44 Cell 138, July 10, 2009 ©2009 Elsevier Inc.virus infection, selectively predispose the host to herpes sim-
plex encephalitis (Casrouge et al., 2006; Zhang et al., 2007).
These new data suggest that we should consider that many 
or all humans are genetically “immunocompromised” to a 
greater or lesser extent for specific infections, including infec-
tion by viruses that constitute our virome. Thus, a virus pres-
ent in all of us may cause disease only in those unfortunate 
enough to have a specific constellation of genes. Therefore, 
attributing a disease to a “viral” cause based on the presence 
or absence of the virus falls by the wayside, especially for 
viruses that infect most or all humans (Table 1). In this view, we 
have only identified the easily detected “viral” diseases—those 
caused by viruses that are virulent in a high enough proportion 
of people to allow informative comparison between infected 
and uninfected persons. Further viral diseases may be await-
ing either the identification of new viruses or the assessment of 
relationships between individual human genes, the virome, and 
specific diseases. A provocative example of this has recently 
been discovered. The new human virus xenotropic murine leu-
kemia virus-related virus (XMLV) (Table 1), recently detected 
in prostate cancer tissues (Urisman et al., 2006; Dong et al., 
2007), is not present in all prostate cancer patients. However, 
it is possible that XMRV causes prostate cancer in individuals 
with a specific immunologic abnormality. Chronic XMRV infec-
tion is strongly associated with homozygous mutations in the 
interferon-regulated antiviral molecule RNaseL, and RNaseL 
mutations predispose the host to prostate cancer (Urisman et 
al., 2006; Dong et al., 2007). Thus, the causal role for a virus 
may be clear only in the light of a patient’s total genomic com-
plement of focal immune abnormalities.
Given the breadth of chronic viral infection (Figure 2, Table 
1), these changes in our understanding of the relationship 
between human genetics and virus-induced disease requires 
that we be open to new ways to look at disease causality. The 
immunologic imprint of chronic virus infection provides one 
potential mechanism by which the virome may contribute to 
a range of inflammatory diseases. Even diseases not gener-
ally considered as inflammatory in nature may be influenced by 
our virome. For example, mice chronically infected with murine 
CMV exhibit hypertension due to alterations in the renin-
angiotensin system that is responsible for regulating systemic 
blood pressure (Cheng et al., 2009). Thus, the existence of a 
viral contribution to our metagenome may exact a large price 
in those of us with specific genetic predispositions to disease. 
The bottom line is that many major diseases that have been 
associated with inflammation—including cardiovascular dis-
ease, neurodegeneration, allergic diseases, cancer, and auto-
immunity—occur in persons that are chronically infected by 
viruses. However, the potential of persisting viruses to contrib-
ute to disease in specific genetic settings has not been defini-
tively examined. Therefore, genome-wide association studies 
should be extended to include variations in the virome as part 
of normal human genetic variation.
The Viral Metagenome Immunologic Imprint
Redefining the normal immune system as bearing the imprint 
of ongoing responses to chronic viruses with very different 
genetic strategies for avoiding sterilizing immunity has impor-
tant implications for how we consider immune interventions 
to prevent or treat infections. The imprint of responses to our 
virome may influence preventative or therapeutic vaccination 
against the chronic viruses themselves but may also change 
how responses occur to unrelated pathogens, viral variants 
that arise during chronic infections with viruses such as HIV or 
HCV, or self-antigens. Our emerging understanding of the differ-
ences between acute and chronic infection provides hope that 
specific interventions such as targeting inhibitory receptors or 
cytokines may, in concert with vaccination, offer effective con-
trol of these pernicious pathogens. However, viral strategies 
such as rapid mutation to diverse quasispecies or the capacity 
to retreat into an immunologically silent latent reservoir will still 
present profound challenges, even if mechanisms regulating T 
and B cell dysfunction during chronic infection can be defined 
and effectively targeted. For example, elimination of HIV might, 
if the virus establishes immunologically silent latency immedi-
ately after initial infection, require enforced reactivation of the 
virus and simultaneous elimination of a rapidly mutating virus. 
Treating or eliminating hepatitis C must similarly deal with the 
genetic variation of the virus. It must also deal with the fact that 
the role of inhibitory receptors in T cell dysfunction may be dif-
ferent between the relevant hepatic T cells and the more easily 
obtained circulating T cells.
The immunologic imprint of responses to our virome needs 
to be taken into account for the development of therapeutic 
as well as preventative vaccines. The recent failure of the ade-
novirus-based HIV vaccine, despite generation of detectable 
immune responses to target antigens, calls to mind the chal-
lenges to be met (Fauci et al., 2008; Walker and Burton, 2008). 
One important issue is whether responses present in persis-
tently infected persons, such as those with persistent adenovi-
rus, may alter the response to antigens in viral vectors derived 
from a persistent virus. For example, antibodies to an adeno-
virus vaccine vector particle can alter dendritic cell-dependent 
T cell responses to vector-encoded antigen (Perreau et al., 
2008). Another issue is whether the imprint of chronic infection 
by viruses unrelated to either the virus being targeted by the 
vaccine or the vaccine vector itself can alter responses. Given 
the breadth of our virome, the imprint of chronic virus infection 
may be a confounding variable in human vaccine responses. 
Yet another issue is the fundamental one of selecting the best 
model systems for analyzing immune responses relevant to 
humans (Virgin, 2007a). As experimental mouse or primate sys-
tems are further and further removed from the chronic infec-
tion-imprinted natural state, will their responses be less and 
less relevant to responses in humans?
Understanding Chronic Virus Infections
Given that chronic virus infections may be harmful in only a lim-
ited number of genetically predisposed persons or may even 
be symbiotic, the costs versus benefits of eliminating chronic 
viruses must be carefully considered. We argue that infections 
that are generally considered harmless or unimportant play a 
role in shaping the normal immune response, at the cost of 
inducing disease in rare individuals with highly specific altera-
tions in immune system genes. No one would doubt the essen-
tial importance of vaccinating against HCV or HIV. But what 
about the other chronic viruses that may be part of our normal 
metagenome and either do not cause disease or cause dis-ease in only a few individuals? Can interventions be targeted 
to those whose genetic constitution renders them specifically 
vulnerable to a given viral infection so that we can eliminate 
disease without eliminating infection in all people? Reformat-
ting the epidemiologic examination of viruses and disease 
to take into account the full genetic background of the host, 
including the virome, is a possibility, but genomic platforms are 
not yet sufficiently robust to make this a reality. The era of per-
sonalized vaccination and immunotherapy may be before us, 
but there is much to learn about viral immunity. Future studies 
need to specifically focus on defining the mechanistic details 
of the disease and immunologic imprint of responses to our 
virome, so that we can distinguish friend from foe and inter-
vene appropriately.
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